

## **Cannabinoid Product Board**

### **“Whereas” statements regarding the CPB’s recommendation on cannabis use for anxiety.**

WHEREAS: Anxiety, when used as a psychiatric diagnosis, encompasses multiple and complex psychiatric and medical disorders;

WHEREAS: Research regarding effective treatment for many anxiety disorders with cannabis products has been difficult to perform and interpret; and,

WHEREAS: Anxiety, which is often a symptom rather than a specific diagnosis, with varied causes, also makes meaningful treatment studies with cannabis products difficult to perform and interpret; and,

WHEREAS: The current, published, scientific literature does not clearly show beneficial impacts on anxiety from treatment with cannabis products, and has identified adverse reactions and worsening of anxiety from treatment with cannabis products;

BE IT RESOLVED: The Utah Cannabinoid Product Board does not find adequate evidence to support the use of cannabis products for the treatment of anxiety.

*Approved by Cannabinoid Product Board on January 12, 2021*